Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo (Q38907955)

7 September 2017

title

Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo (English)

1 reference

7 September 2017

Jianli Zhang

1

1 reference

7 September 2017

Yue Hong

series ordinal

2

1 reference

7 September 2017

Jie Shen

series ordinal

3

1 reference

7 September 2017

publication date

20 February 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

36

1 reference

7 September 2017

issue

7

1 reference

7 September 2017

page(s)

5699-5706

1 reference

7 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

PI3K signalling: the path to discovery and understanding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

PI3K and cancer: lessons, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine: update on a novel Akt inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Current view on the mechanism of action of perifosine in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

MEK targeting in N-RAS mutated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

MEK and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Cordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via activating amp-activated protein kinase (AMPK) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: new implication for Kawasaki disease (KD) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

mTOR inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3244-2

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

21 January 2018

1 reference

12 December 2020

Perifosine sensitizes UVB-induced apoptosis in skin cells: new implication of skin cancer prevention?

1 reference

12 December 2020

Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells

1 reference

12 December 2020

Chemotherapy for advanced non-small-cell lung cancer.

1 reference

12 December 2020

10.1007/S13277-015-3244-2

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1002776475

0 references

1 reference